In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.

Salt Lake City, UT, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, announced today it will ...

In this article, we are going to take a look at where Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) stands against the other stocks. The stock market may have registered losses on Friday ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

On Wednesday, Recursion announced favorable efficacy data in the Phase II trial for REC-994, the company’s lead AI-derived candidate to treat the potentially fatal brain disease, cerebral ...

Aaron Blake is senior political reporter, writing for The Fix. A Minnesota native, he has also written about politics for the Minneapolis Star Tribune and The Hill newspaper. A shocking meeting ...

Blake Lively slammed the "sexist trope" The Hollywood Reporter used to depict the actress in a cover story about her legal battle with Justin Baldoni. Lively claimed she, along with other cast and ...

Blake Lively and Ryan Reynolds are seeking additional protections amid their ongoing legal battle with Justin Baldoni. The couple, who are involved in a complex lawsuit with Lively's "It Ends With ...

Blake Lively filed an amended complaint Tuesday against "It Ends With Us" co-star Justin Baldoni, Wayfarer Studios and various executives that documented new allegations, including shocking ...

Time to pop open your TBR list, because a lot of upcoming book-to-screen adaptations are on the way across loads of genres, from what upcoming Stephen King movies are coming up to the next Hunger ...